Exchange deficiency notices, reverse splits, moves from Nasdaq to OTC and delistings at public biotech companies, newest first.
Listings ·
Nasdaq gave Propanc no 180-day compliance period because it reverse split within the past year. The company says it will appeal by October 30, 2026. Its fiscal 2026 net loss was $18.9 million.
PPCBA distant skyline over open water. Photo: Matt Bango, CC0, via StockSnap
Listings
The proposal goes to a virtual annual meeting on December 18, 2026. The board would pick the ratio and could decide not to split at all.
RVPH
Listings
Nasdaq's Hearings Panel determined to delist Glucotrack common stock after its closing bid price was $0.87 on October 14, 2026, and trading is suspended at the open on October 30, 2026.
GCTK
Listings
Milestone has until April 21, 2027 to close at $1.00 or more for 10 consecutive business days, after 30 consecutive business days below that level.
MIST
Listings
OSR Health, whose shares have traded over the counter since Nasdaq suspended them on August 26, 2026, says it will update shareholders by November 6, 2026 on how it plans to regain a listing.
OSRHThe split cuts aTyr's outstanding common stock from approximately 100.5 million shares to approximately 2.5 million. The 8-K does not give a reason for the ratio.
ATYRThe November 12, 2026 meeting will vote on issuing stock under the Astor notes and warrants, and on reverse splits of up to 1-for-1,000. There were 9,322,805 shares outstanding on the October 23, 2026 record date.
CDTBecause Enlivex already did a reverse split within the past 12 months, it is not entitled to a 180-day period to regain compliance.
ENLVGeoVax can borrow up to $1,000,000 at 12% interest from Bowery Consulting Group, and it agreed to pursue a public offering of at least $5,000,000. The lender designated the new directors.
GOVXThe board will pick a reverse split ratio between 1-for-10 and 1-for-25. Holders also approved up to 11,395,256 shares for warrants issued in August 2026, against 9,093,871 shares outstanding at the record date.
GOVXPulmatrix stockholders approved all nine proposals on October 26, 2026, including a share issue above 20% to Eos holders, certain noteholders and adviser Palladium, and a reverse split of one new share for every 2 to 10. The 8-K says Eos and Pulmatrix holders could end up owning more or less of the combined company if the exchange ratio is adjusted.
PULMAEON Biopharma asked stockholders to approve a reverse stock split of between 1-for-2 and 1-for-100, to be voted on December 15, 2026. The stock last sold at $0.24 on October 23, and NYSE American's cumulative ratio limit counts the company's 1-for-72 split of February 2025.
AEONThe split cuts the share count to about 588,677 from roughly 5,886,774. The stock keeps trading on Nasdaq as ONCO under a new CUSIP.
ONCOSilexion shareholders approved a 500,000,000-share increase in authorized capital and a reverse split. The board chose 1-for-24 from a range of 1-for-15 to 1-for-25. Holders of about 18.6% of shares attended the reconvened meeting, which the articles treat as a quorum.
SLXNTScan's board will set the reverse split ratio between one-for-two and one-for-fifty, and stockholders vote on November 20, 2026. Nasdaq's bid price deadline is February 23, 2027, and the stock closed at $0.2379 on October 12, 2026.
TCRXNasdaq says the stock closed below $1.00 for 30 consecutive business days. Cash fell from $184.8 million at year-end 2025 to $155.5 million at June 30, 2026, and the company says it could seek a reverse stock split.
AKBACitius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million.
CTORCTXRLunai Bioworks will not appeal a Nasdaq staff decision to delist its stock and plans to deregister with the SEC. Trading on Nasdaq is expected to be suspended on October 30, 2026.
LNAINasdaq closed Medicus Pharma's bid price case on October 23, 2026, three days after a delisting letter. The 8-K does not say whether the company now meets the $5 million stockholders' equity standard Nasdaq cited.
MDCXThe split takes effect at 5:00 p.m. Eastern Time on October 26, 2026, and NUWE shares trade split-adjusted from October 27.
NUWEEvery 10 shares of common stock will combine into one share on NYSE American, with the stock trading on a split-adjusted basis from market open on October 26, 2026.
AZTRIssued shares will fall from 24,511,905 to about 1,531,995. The stock stays on the Nasdaq Capital Market under ENLV.
ENLVAlaunos told the SEC on October 21, 2026 that it believes its $350.0 million financing restored compliance with Nasdaq's $2,500,000 equity rule. The same filing says Nasdaq may not agree, and a November 10 hearing was still set.
TCRTThe company says it needs both measures to protect its Nasdaq listing, with 14,473,292 shares already outstanding against 15,900,000 authorized. Shareholders rejected smaller versions in September.
SLXNNasdaq filed Form 25 on Oct. 7, ending a listing that began unravelling over the minimum bid price. The stock trades OTC as SGMOQ after Sangamo agreed to sell its Fabry program to PTC for $111 million in cash.
SGMOQNasdaq gave Mustang Bio until April 12, 2027 to lift its bid price to $1.00. The company has said it intends to do a reverse stock split if necessary.
MBIOMannatech said a Swiss holding company transaction and a pro forma tax adjustment put it back above Nasdaq's stockholders' equity minimum, subject to review and to Nasdaq's view.
MTEXNasdaq confirmed on October 12, 2026 that the matter is closed. The company changed its ADS ratio from 10 to 200 ordinary shares effective September 28, 2026.
IMMNasdaq said the ordinary shares closed below US$1.00 for 30 consecutive business days. The letter has no current effect on the listing or trading.
GDTCNasdaq staff told Alaunos on October 5, 2026 that its securities are subject to delisting under Listing Rule 5550(b)(1). The company plans to request a hearing and says it is working with a financial advisor on potential transactions.
TCRTArtelo was among about 180 Nasdaq companies first identified as below the new threshold. The company gives no market value figure, and the rule is on a temporary stay.
ARTLThe exchange is expected on or about October 26, 2026. Holders must surrender eight old ADSs for one new one, and the release gives no reason for the change.
BDRXEvery 20 shares of common stock will combine into one share at 12:01 a.m. Eastern Time on October 12, 2026. The common stock will keep its Nasdaq Capital Market listing under NXGL with a new CUSIP.
NXGLThe Nasdaq Stock Market has filed a Form 25 to remove Aditxt's common stock from listing, dated October 7, 2026. The form does not say why Nasdaq acted, and the company reported $268,852 of cash at March 31, 2026.
ADTXNasdaq gave Redhill Biopharma until April 5, 2027 to regain the $1.00 minimum bid price, in a letter dated October 6, 2026. The American Depositary Shares keep trading on The Nasdaq Capital Market as RDHL, but the company's cash was last reported at $2.9 million in mid-2025.
RDHLNasdaq signed the Form 25 itself on October 6, 2026, and the form gives no reason. Sangamo's latest annual report warned it might cease operations, liquidate or seek bankruptcy protection.
SGMOQNasdaq staff said Kyntra Bio had not shown compliance with Listing Rule 5450(b) by the September 29, 2026 deadline. A hearing request keeps the stock trading for now.
KYNBA 10-into-1 share consolidation takes effect only if the Class A bid price is below $1.00 for three consecutive trading days within 12 months. The 6-K gives no current share price and does not say whether Nasdaq has sent a notice.
UPCBeyondSpring Inc. received a Nasdaq letter on September 29, 2026 saying its market value of listed securities has been below $35 million for 30 consecutive business days. It has until March 29, 2027 to regain compliance, and its shares keep trading in the meantime.
BYSIDaré Bioscience has until March 29, 2027 to show a $1.00 closing bid price for 10 consecutive business days. A second 180-day period is possible only if it meets the other listing standards and says it will cure the shortfall, by a reverse split if needed. Its cash fell to $12.6 million by June 30, 2026.
DARELantern has until March 24, 2027 to restore the $35,000,000 market value minimum after a Nasdaq notice dated September 25, 2026. Its 2025 net loss was $17.1 million.
LTRNNutriband's public warrants expired on September 30 without extension or repricing. Nasdaq filed a Form 25 to remove them. The company said its common stock is not affected.
NTRBNasdaq filed a Form 25 notice dated 2026-09-30 to strike Abpro Holdings' Class A Common Stock and warrants from listing. The company had already received a delisting notice effective February 23, 2026, and its shares trade on the OTC Pink Limited Market.
ABPOIssued common shares will fall from 4,059,227 to 507,404, subject to fractional-share adjustments.
CMNDNasdaq has given Evogene until March 29, 2027 to lift its ordinary shares back above $1.00. The company says it may consider a reverse split. In 2025 it used $13.5 million in operations, and year-end cash was $13.0 million.
EVGNSciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern.
SPRCNasdaq confirmed on September 29, 2026 that Tevogen meets the $50 million minimum market value of listed securities rule. The company had $1.1 million of cash at June 30, 2026, after cash used in operations of $12.3 million in 2025.
TVGNStockholders voted on September 22, 2026 to raise authorized common shares from 12,500,000 to 100,000,000. The board may now carry out reverse splits at a cumulative ratio up to one-for-twenty.
LABTNasdaq told the company on September 24, 2026 that its shares had closed above $1.00 for 13 straight trading days, closing the matter.
LIMNNasdaq closed the bid price matter on September 25, 2026, after an April notice. The 1-for-80 reverse split took effect on September 10, 2026, and the 2025 net loss was $170.4 million.
GOSSPolyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months.
PLRZThe split takes effect September 28, 2026, to keep the company in compliance with the Nasdaq bid-price rule, and trading on the split-adjusted basis starts September 29.
CDTThe notice, received September 21, 2026, says Calidi does not meet the exchange's stockholders' equity standard. The company must submit a compliance plan by October 21, 2026.
CLDIThe reverse split of Matinas BioPharma Holdings took effect at 12:01 a.m. Eastern Time on September 28, 2026. Every 15 shares of common stock became one share.
MTNBA Nasdaq hearings panel is already weighing a delisting over low shareholders' equity. The closing bid price has been below $1.00 for 30 consecutive business days.
SLXNNasdaq says OTLK closed under $1.00 for 30 straight business days. The company has until March 24, 2027 to cure, and its latest 10-Q carried a going-concern warning.
OTLKClass A shares outstanding will fall from 380,623,358 to 12,687,445 when the 30-for-1 consolidation takes effect on October 1, 2026. Shareholders approved it on September 5, 2026, and authorised share capital rises to US$15,090,000.
BGMThe September 2026 deck's risk list includes a possible reverse stock split to meet Nasdaq listing requirements.
XBIOThe company effected the reverse split on September 17, 2026, and filed a certificate removing the terms of fourteen older preferred stock series from its charter, leaving about 520,088 common shares outstanding.
JAGXNasdaq's September 18, 2026 letter says the ADSs closed at $1.00 or more for 19 consecutive business days. The matter is closed.
SCNIShareholders' equity of $1,075,007 in the 10-K for the year ended June 30, 2026 fell below the $2,500,000 Nasdaq minimum. The company has 45 calendar days to submit a plan.
INMNasdaq staff says Moleculin is not eligible for a compliance period because it effected a 1-for-25 reverse stock split on December 1, 2025. The company plans to request a hearing, which stays any delisting action while it is pending.
MBRXNasdaq told BeyondSpring on September 17, 2026 that its ordinary shares closed below $1.00 for 30 consecutive business days. Trading continues during a 180 calendar day compliance period that ends March 16, 2027.
BYSINasdaq gives Filana until March 16, 2027 to regain compliance. Cash and equivalents fell to $86.6 million at March 31, 2026, from $128.6 million at the end of 2024.
FLNAAt its September 17, 2026 annual meeting, stockholders approved a reverse split at a ratio of 1-for-2 to 1-for-20 and raised authorized common shares from 75,000,000 to 125,000,000.
SNGXThe Nasdaq Stock Market said on September 17, 2026 that it will delist the common stock of Aditxt, Inc. The stock was suspended on June 25, 2026 and has not traded on Nasdaq since then.
ADTXPasithea Therapeutics said its KTTAW warrants will expire on September 17, 2026 and stop trading on Nasdaq, while its common stock keeps trading as KTTA.
KTTAThe board approved a one-for-fifteen reverse split of the common stock, effective 12:01 a.m. Eastern Time on September 28, 2026, under the existing MTNB symbol.
MTNBNasdaq says the closing bid has been below $1 for 30 consecutive business days. The company completed a 1-for-6 reverse split in June 2025 and plans to seek approval for another at its next annual meeting.
BBLGThe company plans a public offering of approximately $5 million, and its projections show stockholders' equity of approximately $5.1 million through June 30, 2027.
ISPCA September 2026 report sets out a 1-for-3,000 reverse split of Can-Fite's ordinary shares in January 2026, and a change that cut each ADS from 300 ordinary shares to two. The company also lists the risk of failing NYSE American continued listing standards.
CANFThe deal pays $2,000,000 in cash, including milestone payments, and $2,500,000 in stock held in a five-year escrow.
ISPCThe exchange says stockholders' equity was $1.8 million at June 30, 2026, below the $2.0 million standard, and the listing continues under an accepted plan through October 2, 2027.
MTNBNasdaq told Quince Therapeutics its stockholders' equity was ($35,324,000), below the $10,000,000 minimum. The company has until October 15, 2026 to submit a compliance plan and has filed an initial listing application that would come with a name change.
IRLAQNCXThe consulting agreement covers up to 10 news releases over 3 months starting 9/3/2026. The fee is non-refundable, and the agreement says the services are promotional.
XRTXCash rose to $8,526 thousand at June 30, 2026, from $3,125 thousand at year end, while the six-month loss was $2,942 thousand. Most of the cash came from a $10.0 million equity line that has since ended.
PRFXNasdaq flagged a missing June-quarter 10-Q on Aug. 21. Days later the company announced a reverse split that cut its shares outstanding to about 1.38 million to fix a separate bid-price shortfall.
BRTXNasdaq says Anavex has regained compliance after filing overdue quarterly reports, but the release does not say why they were late.
AVXLQuantum BioPharma has applied to delist its Class B shares from the Canadian Securities Exchange, with September 4, 2026 expected as the last trading day, subject to approval. The company's own release does not give the trading volumes behind the decision.
QNTMShareholders approved authority for a reverse split tied to an uplisting, and a special committee to negotiate retiring the Series B preferred stock. The company's release reports no vote counts.
ETSTNYSE American notified Oragenics on August 26, 2026 that it is not in compliance with two continued listing standards on stockholders' equity. The company has 45 days to submit a compliance plan and says it intends to do so.
OGENThe reverse split took effect August 28, 2026, with trading on a split-adjusted basis from August 31, 2026, and shares outstanding were reduced from 11,972,157 to approximately 798,144.
GCTKEach 12 shares will combine into one, which would reduce the 11,084,616 common shares outstanding to about 923,718. The release says trading begins on the Nasdaq Capital Market on September 1, 2026, under the FEED symbol.
FEEDNasdaq says Shuttle no longer meets Listing Rule 5250(c)(1) because its quarterly report for the period ended June 30, 2026 is late. A plan to regain compliance is due October 27, 2026.
SHPHThe July 3, 2026 agreement allows pre-paid purchases of up to $31,500,000 before an original issue discount. The August 27 amendment restores the $0.20 floor after a 1-for-80 share consolidation had raised it to $16.00.
SXTCThe Nasdaq Hearings Panel scheduled OSR Health's hearing for September 29, 2026, while trading in its securities remains suspended under the company's own filing.
OSRHArtelo will combine every nine shares of common stock into one, with split-adjusted trading beginning August 31, 2026, and about 547,774 shares outstanding afterward.
ARTLThe split takes effect August 31, 2026 under the same VBIO symbol, and the company says it aims to meet the Nasdaq minimum bid price rule.
VBIONasdaq flagged Senti's sub-$1 share price and a stockholders' deficit below the $2.5 million minimum. The bid-price clock runs to Feb. 23, 2027; the equity plan is due Oct. 11.
SNTIThe split takes effect August 27, 2026 and reduces outstanding shares from approximately 27.7 million to approximately 5.5 million, aimed at Nasdaq's minimum bid price requirement.
IDXGNasdaq extended the Ensysce Biosciences bid price deadline to February 22, 2027, and said the company must meet initial listing criteria after its Cy Biopharma acquisition.
ENSCThe split took effect Aug. 26 and cut Class A shares to about 3.04 million. Three weeks later the company reported that its HLHS trial missed its primary endpoint.
LGVNNasdaq staff said VivoSim Labs has until February 16, 2027 to show a closing bid price of at least $1 for ten consecutive business days, and the company is weighing a reverse split.
VIVSNasdaq granted Pasithea Therapeutics 180 more days, to February 16, 2027, to regain the $1.00 minimum closing bid price required for continued listing.
KTTANYSE Regulation's August 19, 2026 letter says the company resolved deficiencies under two continued listing standards. A new lapse within 12 months could bring faster action.
AZTRSplit-adjusted shares will trade under the existing KAPA symbol at market open on September 1, 2026, and the company says the split is meant to help it keep its NYSE American listing.
KAPANasdaq notified Estrella on August 17, 2026 that its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance. Its year-end 2025 cash was $1.4 million.
ESLANasdaq told Adial on August 18, 2026 that it no longer meets the $2,500,000 stockholders' equity requirement. The company says it anticipates regaining compliance once holders approve conversion of its Series A Non-Voting Convertible Preferred Stock.
ADILNasdaq gave Citius Pharmaceuticals until February 8, 2027 to show compliance with its $1.00 minimum bid price. The 8-K gives no closing price and no plan, and the company says it cannot assure it will regain compliance.
CTXRCTORProfusa reported cash of $719,000 at June 30, 2026, and said it expects stockholders' equity of $28.4 million as of July 31, 2026.
PFSACuranex's 1-for-20 reverse split took effect on August 20, 2026. Nasdaq closed its bid-price matter on September 3, after the stock traded at or above $1.00 for ten consecutive business days.
CURXNasdaq staff said OSR Health did not regain compliance with the $1.00 minimum bid price, and trading in its common stock and warrants will be suspended on August 26, 2026.
OSRHNasdaq said on August 18, 2026 that the ADSs are still below $1.00 but the company is eligible for 180 more calendar days.
MREONasdaq said on August 18, 2026 that Skye Bioscience's stockholders' equity was a deficit of $497,307 at June 30, 2026, below the $2,500,000 minimum. The company has until October 2, 2026 to submit a plan to regain compliance.
SKYENasdaq gave BullFrog AI until February 8, 2027 to regain the $1.00 minimum bid price. Stockholders approved a reverse stock split at a ratio of not less than 1-to-2 and not more than 1-to-15.
BFRGLiminatus will cut its shares 50 to 1 at the close of trading on August 20, 2026. The Nasdaq Panel now requires a $1.00 closing bid for ten consecutive trading days by September 3, after notices on market value and bid price.
LIMNThe Hearings Advisor told the company on August 17, 2026 that staff confirmed compliance with Listing Rule 5550(a)(2), and the requested hearing was cancelled.
LEXXXORTX ended June 30, 2026 with $994,045 in cash after a $5,000,000 public offering, and the going-concern note stays. Operations used $3,768,993 in the six months.
XRTXThe company reported stockholders' equity of negative $415,000 at June 30, 2026, below Nasdaq's $2,500,000 minimum, and must submit a compliance plan by September 28, 2026.
ADGMCASI Pharmaceuticals had $3.8 million of cash at June 30, 2026, after its ordinary shares left Nasdaq and began quoting on the OTCQB. Its first-half release says recurring operating losses have raised substantial doubt about its ability to continue as a going concern.
CASIFSkye Bioscience's investor deck describes a U.K. scheme of arrangement to combine with Redx Pharma, a concurrent financing totaling $125 million, and a contingent value right for former Skye holders. The deck says Skye is discontinuing its CBeyond trial of nimacimab.
SKYECash and short-term investments stood at $7,393 thousand and $54,446 thousand at June 30, 2026. The shares were consolidated twelve-for-one in January.
MSCLThe company said its June offering and move to the Nasdaq Capital Market strengthened its balance sheet. Cash of $62.0 million is expected to fund operations into mid-2028.
ELOXHolders will vote on September 22, 2026 on raising authorized common stock from 12,500,000 shares and on a reverse split of up to 1-for-20.
LABTThe notice lists one holder of record of the ordinary shares and is dated August 7, 2026. Wave Life Sciences Ltd. reported a net loss of $204.4 million for 2025.
WVENasdaq's August 4, 2026 letter says the closing bid price held at $1.00 or more for ten straight business days. The 8-K gives no share price, and the company's latest annual report shows $3.5 million of cash and a material weakness in its controls.
NIKINasdaq's August 5, 2026 letter says the Class A ordinary shares closed at $1.00 or more for ten straight business days. The shares stay on the Nasdaq Capital Market.
ZYBTNasdaq's Hearings Panel confirmed on August 4, 2026 that Genprex regained the $1.00 minimum bid price, but the panel keeps jurisdiction until December 7, 2026.
GNPXNasdaq gave Vistagen until February 1, 2027 to restore a $1.00 minimum bid, while its 10-K says its lead Phase 3 study missed the primary endpoint. It used $42.1 million in operations in its last fiscal year.
VTGNAuthorized common shares rise from 150,000,000. The August 5, 2026 special meeting also approved an amendment to the 2021 Stock Option and Incentive Plan.
AURANYSE Regulation confirmed that AEON resolved the stockholders' equity deficiencies it had reported, after an offering that closed on July 15, 2026. The company expects the below-compliance indicator to be removed from its trading symbol.
AEONThe split takes effect at 10:00 a.m. Eastern Time on July 31, 2026, and shares are expected to trade split-adjusted on August 4, 2026 under AEMD.
AEMDNasdaq told Mira Pharmaceuticals on July 27, 2026 that its common stock no longer meets the $1 minimum bid price. The company has until January 25, 2027 to regain compliance, and it reported a 2025 net loss of $10.4 million on cash used in operations of $4.7 million.
MIRANasdaq said PDS Biotechnology's common stock closed below $1.00 for 30 consecutive business days. The letter has no immediate effect on its Nasdaq Capital Market listing, and the company names a reverse stock split as one option.
PDSBEvogene's board backs its own seven-person slate over a rival four-person slate at a September 4 meeting, and asks for 120,000,000 more authorized shares and a reverse split of 1-for-2 to 1-for-15. Year-end cash fell to $13.0 million in 2025.
EVGNThe panel's July 29, 2026 decision lets Genprex stay listed on the Nasdaq Capital Market while it keeps a closing bid of at least $1.00 each trading day until December 7, 2026.
GNPXThe quarterly cash flow report also shows an A$3,982,992 tax incentive refund and says the company is evaluating strategic and funding alternatives.
ATHShares outstanding will drop from 24,787,446 to 1,652,518. The company expects to seek a Nasdaq hearing if it gets a delisting notice.
LEXXNasdaq says Traws has until January 25, 2027 to regain compliance with the minimum bid price requirement, and that its listing remains fully effective for now.
TRAWCelularity (Nasdaq: CELU) was told on July 23, 2026 that its Class A common stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its listing, the company says.
CELUEarth Science Tech's board wants a non-binding stockholder signal on a reverse split to meet the bid price test for an uplisting. The company says it is not currently a listed issuer, and the proxy's notice gives no split ratio.
ETSTBGM Group filed the annual report for the year ended September 30, 2025 on July 21, 2026, and Nasdaq said the filing cured the lapse on July 24. The same report shows a net loss of $19.9 million, up from $1.4 million.
BGMThe split became effective July 30, 2026, and the common stock began trading split-adjusted on July 31 under the existing CLDI symbol.
CLDINasdaq said VivoSim Labs no longer met the $2,500,000 stockholders' equity minimum on July 20, 2026, and the company said its equity exceeded $2.5 million after July transactions.
VIVSThe one-for-ten split took effect on July 24, 2026, and the stock trades on NYSE American under APUS on a split-adjusted basis, with par value cut to $0.001.
APUSNasdaq told Standard BioTools on July 22, 2026 that its shares closed below $1.00 for 30 days. The company has until January 19, 2027 to regain compliance, and its own filing says it cannot be sure it will.
LABNasdaq told Oncolytics its stock closed below $1.00 for 30 consecutive business days. The letter does not change the listing for now, but the company's annual report says its $5.2 million of cash cannot fund planned operations for 12 months, and that doubt about its ability to continue as a going concern is substantial.
ONCYNasdaq staff says the bid price closed below $1.00 for 30 consecutive business days and that FibroBiologics gets no 180-day compliance period after a reverse stock split. The company intends to request a hearing.
FBLGNasdaq staff confirmed on July 20, 2026 that XTL meets four listing rules. Another equity shortfall within the year would lead to a delist determination.
XTLBNasdaq told Rockwell Medical on July 16, 2026 that the company had regained compliance with the $1.00 minimum bid price, and closed the matter. The 8-K does not give the closing prices behind that finding.
RMTINasdaq told Daré Bioscience (Nasdaq: DARE) on July 13, 2026 that it no longer meets Listing Rule 5550(b). The company intends to request a hearing, which would stay delisting while the panel decides.
DAREThe split takes effect July 17, 2026 and trades on a split-adjusted basis from July 20, reducing outstanding shares to approximately 631,077.
CDTThe split, approved by the board on July 2, 2026, moves shares outstanding from 11,108,577 to approximately 504,936, and the company released an investor presentation the same day.
GNPXNasdaq said on July 8, 2026 that the matter is closed. The company had been notified of the shortfall on June 18, 2026.
APLMThe company said on July 13, 2026 that its one-for-ten reverse split would take effect on July 24, after a March 2026 target passed without a filing.
APUSNasdaq told ENDRA on July 8, 2026 that it regained compliance with the $2,500,000 minimum stockholders' equity requirement, but the company will be under a one-year panel monitor.
NDRAAquaBounty's board decided on July 6, 2026 not to carry out a reverse split of 1-for-5 to 1-for-20 that stockholders approved, and that authority expires July 31, 2026.
AQBOragenics appointed John Spencer, its Senior Controller, as Chief Financial Officer effective July 1, 2026. The company's June 29, 2026 annual meeting included a vote on authority for a reverse stock split of one-for-two to one-for-fifty.
OGENIn a letter to shareholders, CEO Seamus Lagan reported first quarter 2026 net revenues of about $5.1 million, completed a 1:3,000 reverse stock split, and said FOXO is considering an uplisting to a recognized exchange before the end of 2026.
FOXOThe July 6, 2026 notice lists approximately 153 holders of record of its common shares.
CSCIShareholders approved the second tranche on June 18, 2026, and the investor now holds a $2.875 million note convertible at 93% of recent trading prices.
GELSThe reverse split of FOXO's Class A common stock took effect at 4:01 p.m. ET on June 30, 2026. Shares trade on a split-adjusted basis under the temporary symbol FOXOD until the symbol reverts to FOXO on or about July 20, 2026.
FOXOA Nasdaq Hearings Panel found HCW Biologics (Nasdaq: HCWB) back in compliance with the minimum bid price rule. The company faces a mandatory panel monitor and will effect a one-for-six reverse stock split on June 30, 2026.
HCWBRockwell Medical's one-for-ten reverse split takes effect at 12:01 a.m. Eastern Time on July 1, 2026. The certificate was filed June 24, and the company says fractional shares will be paid in cash at the June 30 closing price, adjusted by the company.
RMTINYSE American says Matinas BioPharma fell short of two stockholders' equity standards and accepted its compliance plan, with a plan period through October 2, 2027.
MTNBThe split takes effect at 5:00 p.m. Eastern Time on June 25, 2026, and NUWE shares trade split-adjusted from June 26.
NUWEStockholders approved raising authorized common stock from 350,000,000 to 500,000,000 at a June 17, 2026 meeting, with 88,853,129 votes against. The 8-K does not say how many shares are outstanding or planned for issue.
AKBAStockholders approved raising authorized common stock from 400,000,000 to 800,000,000 at the June 18, 2026 meeting; 345,024,351 shares were outstanding on the April 20 record date. A sales supplement filed June 22 covers up to $135.0 million of stock sales through TD Securities (U.S.A.) LLC.
ALLOStockholders voted on June 17, 2026 to raise authorized common stock from 300,000,000 to 600,000,000 shares. The 8-K does not say what the company plans to do with the extra shares.
CTMXThe annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026.
ELDNProvectus holders authorized a reverse split of between 1-for-10 and 1-for-50, with the ratio left to the board, and a matching cut in authorized shares. The company had $251,291 of cash at December 31, 2025, and its net loss widened to $5.4 million.
PVCTNasdaq told Silo it regained compliance with the minimum closing bid price requirement as of June 17, 2026, and the matter is now closed.
SILONasdaq started a process that could lead to delisting after Dyadic missed the June 17, 2026 deadline to meet the $1.00 minimum bid price. The company plans to request a hearing, and the request automatically stays any delisting action until the panel decides.
DYAIThe annual meeting on June 16, 2026 also elected nine directors and ratified KPMG LLP as auditor.
XNCROutstanding shares will fall from about 17,506,577 to about 1,750,789. The stock stays on the Nasdaq Capital Market as LABT.
LABTThe NYSE American said on June 12, 2026 that AIM had resolved its stockholders' equity deficiencies after a series of share sales and warrant exercises in May and June.
AIMHolders cast 16,993,038 votes for the reverse split and 6,597,036 against it at the June 12, 2026 annual meeting. The 8-K reports the result but gives no split ratio and no effective date.
RMTIThe company's common stock traded below $1.00 for 30 consecutive business days, and it has 180 calendar days to regain compliance.
ADGMA June 10, 2026 Nasdaq letter said Genprex would be delisted unless it requested a hearing, because its stock closed under $1.00 for 30 consecutive business days and it had a reverse split on October 21, 2025.
GNPXNasdaq told Soligenix on June 10, 2026 that its stock has closed below the $1.00 minimum bid price, and the company has until December 7, 2026 to regain compliance. Its board then ended the HyBryte development program, after an interim analysis in a Phase 3 trial recommended stopping it for futility.
SNGXNasdaq granted BioCardia until October 7, 2026 to regain compliance. The company says at-the-market sales with H.C. Wainwright & Co. brought net proceeds of $4.9 million and that it believes equity now exceeds $2.5 million.
BCDANasdaq told Celularity on June 9, 2026 that its market value of listed securities was below the $35 million minimum for 30 consecutive business days. The notice does not delist the stock.
CELUAnnexon's stockholders approved raising authorized common stock from 300,000,000 to 500,000,000 shares on June 11, 2026, with 8,795,454 abstentions and no reason given for the increase.
ANNXCuprina said Nasdaq staff told its hearings department the bid price shortfall was cured, and a July 7, 2026 panel hearing was cancelled. The release does not say what moved the share price, and year-end cash was $2.4 million against cash used in operations of $7.1 million.
CUPRShareholders of both companies approved the all-stock merger on June 9, 2026. The release gives no exchange ratio, and the company's 2025 research spending was $352,879, down from $2.2 million.
NIKISolid Biosciences stockholders voted at the June 10, 2026 annual meeting to double authorized common stock to 480,000,000 shares. The vote drew 893,360 votes against, and the say-on-pay vote drew 6,203,634 against.
SLDBVoyager Therapeutics' stockholders approved on June 9, 2026 an increase in authorized common stock from 120,000,000 to 240,000,000 shares, and in total authorized capital stock from 125,000,000 to 245,000,000. The 8-K gives no reason for the increase.
VYGRStockholders approved a reverse split at a fixed ratio between 1-for-2 and 1-for-20, but the board has no present intention to carry it out in the next 12 months.
BJDXNasdaq notified Jasper (JSPR) on June 3, 2026 that its voting common stock closed below $1.00 for thirty consecutive business days. The notice has no immediate effect on trading; a reverse stock split is among the options named.
JSPRCommon stock authorized rises from 300,000,000 shares. Relay filed the amendment in Delaware on June 9, 2026.
RLAYAt its June 8, 2026 annual meeting, MetaVia stockholders approved a reverse split of 5 to 22 shares into one, with the ratio left to the board, and 200,000 more shares for the equity plan.
MTVANasdaq gave aTyr Pharma until November 30, 2026 to regain the $1.00 minimum bid price, and the company says it may use a reverse stock split. Its lead drug missed the primary endpoint of its Phase 3 trial in September 2025.
ATYRSavara stockholders approved doubling authorized common stock to 600,000,000 shares. The 8-K gives no reason for the increase, and it also reports a new CFO and COO effective July 15, 2026, after the current CFO resigns for health reasons.
SVRAThe amended 2024 plan also drops a cap on its annual share increase. The vote came at the June 3, 2026 annual meeting.
OKURTrevi stockholders voted to double authorized common stock to 400,000,000 shares and to add 8,000,000 shares to the stock incentive plan. The lead cough drug has no Phase 3 results yet, and the 2025 net loss was $42.8 million.
TRVIThe Nevada certificate took effect on June 2, 2026, and shares began trading split-adjusted on Nasdaq on June 3. The ticker stays SILO under a new CUSIP number.
SILOThe 8-K reports the May 28, 2026 annual meeting vote counts, including a reverse split ratio of 1-for-5 to 1-for-15 set at the Board's discretion.
ENVBAbpro Holdings said Nasdaq's Listing and Hearing Review Council reaffirmed the panel's decision to delist its common stock and public warrants.
ABPOThe company did not file its quarterly report for the period ended March 31, 2026 on time, and it has until July 20, 2026 to submit a plan to regain compliance.
CDTSilexion's 1-for-10 reverse share split took effect after the close of trading on May 28, 2026, and the company's warrants were repriced ten-fold with it. By autumn the company was asking shareholders for another split.
SLXNAditxt, Inc. received a Nasdaq letter on May 27, 2026 citing stockholders' equity of $(35,174,386) for the period ended March 31, 2026. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 11, 2026.
ADTXAt its May 27, 2026 annual meeting, Dermata Therapeutics shareholders approved raising the share reserve of its 2021 equity plan to 402,214 shares and repricing warrants for up to 120,734 shares. Three Class II directors were elected.
DRMASINTX Technologies received a Nasdaq notice on May 22, 2026 that its stockholders' equity, about $904,000 at March 31, 2026, is below the $2.5 million minimum. It has until July 6, 2026 to submit a plan to regain compliance, and its 2025 annual report carries a going-concern paragraph.
SINTNasdaq said Ensysce Biosciences must submit a plan by July 6, 2026, to regain compliance with its $2.5 million stockholders' equity requirement, or face delisting.
ENSCNasdaq told TransCode on May 19, 2026 that its stockholders' equity of $1,251,427 is below the $2,500,000 minimum. The company has until July 3, 2026 to submit a plan to regain compliance, and its equity had been $10,335,466 at December 31, 2025.
RNAZTempest reported $822,000 of stockholders' equity against Nasdaq's $2,500,000 minimum, and two director resignations leave it short of several board rules. Its 10-K already carried a going-concern warning.
TPSTThe Board fixed the ratio under a stockholder authority approved April 30, 2026, to help keep the stock above Nasdaq's $1.00 minimum bid price.
ONCOThe split is part of the company's plan to regain compliance with Nasdaq's minimum bid price rule. Issued shares fall from 10,190,337 to about 1,019,033.
CMNDAuthorized common stock rises from 115,000,000 to 215,000,000 shares, against 103,882,937 shares outstanding at the March 25, 2026 record date.
LRMRPalatin will switch from NYSE American to the Nasdaq Capital Market, with its last NYSE American trading day on May 28, 2026. The move needs no shareholder action, but the company's annual report carries a going-concern warning.
PTNNervGen's first-quarter net loss narrowed on a non-cash warrant gain, while its annual filing shows a 2025 net loss of CAD 44.1 million. The company says all its clinical plans remain subject to more funding.
NGENNasdaq says Skye's stockholders' equity of $9,011,804, reported for the quarter ended March 31, 2026, is below the $10,000,000 Global Market minimum. The company has until June 29, 2026 to submit a plan.
SKYERani Therapeutics (Nasdaq: RANI) has until November 9, 2026, to regain bid price compliance. It also reported cash, cash equivalents and marketable securities of $43.4 million and a first quarter net loss of $8.0 million.
RANINasdaq said the ordinary shares closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing or trading.
ENLVAditxt, Inc. said it will effect a 1-for-27 reverse split of its common stock at the opening of trading on May 18, 2026. The company says the split is primarily intended to bring it into compliance with Nasdaq's minimum bid price requirement.
ADTXThe 6% Convertible Exchangeable Preferred Stock, under the symbol BGMSP, stopped trading in March. The common stock, BGMS, remains listed, and first-quarter product revenue was $0.8 million.
BGMSCuprina holders approved a share consolidation, raised Class B votes from 10 to 100 per share and allowed share issues of 20% or more of Class A shares. About 2.79% of the Class A votes were represented at the meeting.
CUPRRevenue reached $3.2 million and gross margin 69.6%, while the operating loss narrowed to $1.5 million and cash and investments totaled $7.5 million.
LGMKThe filing, dated May 11, 2026, relies on the SEC rule for a voluntary withdrawal by the issuer. It covers American Depositary Shares, each representing 10 ordinary shares.
PRTCNasdaq staff said on May 7, 2026 that SciSparc now meets the $2,500,000 stockholders' equity standard, but the letter is conditional. Delisting is possible if the company's next periodic report does not show compliance.
SPRCE.F. Hutton & Co. is the exclusive placement agent, and the company expects the offering to close on or about May 11, 2026.
ISPCNasdaq told Humacyte on May 4, 2026 that its common stock closed below $1.00 for 30 consecutive business days. The company has until November 2, 2026 to regain compliance, and the notice has no immediate effect on its listing.
HUMAA proxy supplement corrects a typographical error that showed a 1-for-50 maximum on the proxy card and notice before the May 28, 2026 annual meeting.
ENVBDEK:Rockwell Medical's proxy asks holders to approve a reverse split at a virtual meeting on June 12, 2026. Approval needs a majority of the votes cast, and the company's 2025 net loss was $5.3 million.
RMTICorMedix wants stockholders to ratify earlier changes to its Series E and Series C-3 preferred stock, and to let preferred holders alone approve future changes to those terms.
CRMDPureTech will delist its American Depositary Shares from Nasdaq and keep its London listing. The Form 25 is expected around May 11, 2026, with the last Nasdaq trading day around May 20, and the company plans to deregister with the SEC afterward.
PRTCNasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until October 19, 2026 to cure, while its auditor has flagged going-concern doubt and its parent funds most operations.
CTORNasdaq's notice dated April 27, 2026 says the ordinary shares closed at $1.00 or more for 10 consecutive business days. The matter is closed.
IFRXAfter the split, the company's 52,639,796 shares become 1,316,032 shares, and the stock trades split-adjusted from April 28, 2026.
ISPCTevogen received two Nasdaq notices in April 2026 saying it no longer meets the $50 million listed-securities market value requirement or the $15 million publicly held shares requirement. It has until October 13 and October 14, 2026 to regain compliance with each.
TVGNNYSE Regulation told Apimeds Pharmaceuticals US on April 17, 2026 that it had not filed its 2025 annual report on time. The company has until October 15, 2026 to file, its stock carries a ".LF" tag, and a trading halt that began April 2 is still in effect.
APUSCue Biopharma's 1-for-30 reverse split takes effect at 5:00 p.m. Eastern Time on April 23, 2026. The company says it is meant to restore compliance with Nasdaq's minimum bid price, and its filing still carries a going-concern determination.
CUEShareholders approved raising authorized common stock from 200,000,000 to 400,000,000 shares, against 130,105,177 shares outstanding at the March 13, 2026 record date.
ALTMustang Bio's common stock closed below $1.00 for 30 consecutive business days, and the company has until October 12, 2026 to regain compliance with the Nasdaq minimum bid price rule.
MBIOCue Biopharma holders approved a reverse split at a ratio between 1-for-30 and 1-for-50. The board will pick the ratio and the timing without another stockholder vote, and the filing does not say why the split is wanted.
CUENasdaq says Alaunos does not meet its $2,500,000 minimum for stockholders' equity, and the company plans to submit a compliance plan.
TCRTThe April 2, 2026 letter cites Listing Rule 5450(b)(3)(A) and revenue of FibroGen International held for sale. Kyntra Bio has 45 days, until May 18, 2026, to submit a plan to regain compliance.
KYNBGossamer Bio (Nasdaq: GOSS) says its stock did not maintain a $1.00 minimum bid price for 30 consecutive business days. It has 180 calendar days to regain compliance and may be eligible for an additional 180 days.
GOSSNasdaq confirmed that Artelo Biosciences has regained compliance with its equity and annual meeting rules. The company is now subject to a one-year panel monitor.
ARTLNYSE American says Matinas BioPharma is out of compliance with three stockholders' equity standards, with equity of $4.83 million at December 31, 2025, and a plan due by May 2, 2026.
MTNBThe notice cites a stockholders' deficit of approximately $55 million as of December 31, 2025. AEON keeps its listing and has until August 3, 2026 to regain compliance.
AEONNasdaq told InMed on March 27, 2026 that its shares closed below $1.00 for 30 consecutive trading days. The company has 180 calendar days to regain compliance and keeps trading as INM.
INMDyadic received a Nasdaq notice on March 27, 2026 that it is out of compliance with Listing Rule 5550(b). It has until May 11, 2026 to submit a plan to regain compliance, and a separate bid price deadline of June 17, 2026 also stands.
DYAIOrdinary shares rose to 5,667,995,734 from 809,418,734 in six months. Nasdaq confirmed on 18 December 2025 that the company had regained compliance with Listing Rule 5550(b).
KZIAThe board says SEC reporting costs are no longer in the best interests of the company and its stockholders. ZIVO plans to file the form on or around March 30, 2026.
ZIVOQuantum BioPharma reports $11.3 million in cash and digital assets at the filing date and says cash lasts beyond January 2028. Its annual report shows year-end cash of $1.9 million, and the release does not split out the digital assets.
QNTMAll five resolutions passed at the March 24, 2026 annual meeting, including a share reclassification and a share consolidation.
ZYBTNasdaq staff says Ernexa's stock failed to maintain a $1.00 minimum bid price for 30 consecutive business days, and that the company is not eligible for a 180-calendar day compliance period because of a reverse stock split in the past year. The company plans to request a hearing.
ERNAThe change has the same effect as a one-for-four reverse ADS split. The ordinary shares are not affected.
XTLBNasdaq told Skye Bioscience (Nasdaq: SKYE) its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and says it will consider its options.
SKYEThe March 19, 2026 release recalls an August 2025 ADS ratio change that worked as a one-for-four reverse ADS split.
CMMBThe change, aimed at Nasdaq's $1.00 minimum bid price, is expected on or about April 6, 2026. Holders must exchange five old ADRs for one new one, and the company says it cannot guarantee the change will work.
BDRXThe ADSs held a closing bid of $1.00 or more for at least 10 consecutive business days, reached on March 13, 2026. The company is now compliant with applicable listing standards.
PPBTNasdaq granted VYNE an extra 180 calendar days, until September 7, 2026, to meet the $1.00 minimum bid price. Its 2025 net loss was $26,483 thousand, and the company says its cash is enough only through the closing of its planned merger with Yarrow Biosciences.
YARWLongeveron told Nasdaq on March 4, 2026 that it was temporarily out of compliance after director Richard Kender resigned from its audit committee. The company had $19.2 million of cash at December 31, 2024, and its annual report projected that cash would last only into the fourth quarter of 2025.
LGVNAnebulo's March 2, 2026 Form 15 puts its SEC reporting duties to an end and gives 71 holders of record for its common stock, while the company's last reported cash figure was $9.0 million at December 31, 2025.
ANEBNasdaq says the stock closed below $1.00 for 30 consecutive business days and that its market value of listed securities stayed below $35 million. The company has until August 25, 2026 on both, and its auditor has raised going-concern doubt.
JUNSAltamira Therapeutics filed a Form 15 dated February 27, 2026, to terminate its registration or suspend its duty to file reports with the SEC. The form lists 48 holders of record, and the company's last business description, from April 2025, still calls its lead programs preclinical.
CYTOFRegentis Biomaterials said on February 24, 2026 that its auditor's opinion on the 2025 financial statements carries a going concern qualification. The company reported $7.4 million in cash at December 31, 2025, and its pivotal knee cartilage trial is still enrolling.
RGNTShareholders gave Psyence's board authority to consolidate the common shares at a ratio of up to 250:1, but the board has not set a ratio or timing, and the company says a consolidation may never happen.
PBMNasdaq says Outlook's stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its Nasdaq Capital Market listing, and a second 180-day period may be available.
OTLKAtossa Therapeutics received a Nasdaq letter on February 17, 2026 saying it regained the $1.00 minimum closing bid price. The stock met the test on February 13, 2026, the last trading day before the extended deadline, after a February 2025 notice and an extension granted in August 2025.
ATOSMereo BioPharma's American Depositary Shares failed to hold a $1.00 minimum bid price for 30 consecutive business days, and Nasdaq gave the company until August 17, 2026 to regain compliance. The company's 2024 annual report shows a net loss of $43.3 million and $69.8 million of cash.
MREOAnebulo filed a Form 25 on February 17, 2026 to withdraw its common stock from Nasdaq as a voluntary withdrawal, while its lead drug candidate remains at an early stage and its cash fell in the second half of 2025.
ANEBNasdaq told Citius Pharmaceuticals on February 9, 2026 that its stock had closed below $1.00 for 30 consecutive business days, and the company has until August 10, 2026 to regain compliance. The same filing reports $3.9 million in first-quarter revenue from LYMPHIR, against $7.7 million in cash.
CTXRNasdaq staff decided on February 6, 2026 to delist Lunai Bioworks, saying a reverse stock split in September 2025 bars the company from the usual 180-day cure period. The company has asked for a hearing, which pauses a February 18 trading suspension.
LNAINasdaq told Vistagen on Feb 3, 2026, that its stock had closed below $1.00 for 30 consecutive business days. The company has until Aug 3, 2026, to regain compliance, and its last annual report carried a going-concern warning.
VTGNAnebulo's board approved leaving Nasdaq and ending SEC reporting, with a Form 25 due about February 17, 2026 and a Form 15 about February 27, while its lead drug candidate is still in early clinical work.
ANEBPolaryx began trading on Nasdaq on February 2, 2026 without an underwriter, and the company received no money from the listing.
PLYXNasdaq told Tenaya Therapeutics on January 28, 2026 that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until July 27, 2026 to regain compliance, and an 8-K filed January 30 also adds 2,161,000 shares to its inducement equity plan.
TNYAUMeWorld moved its legal home from the British Virgin Islands to Delaware, changed its name and began trading as UMEW on the OTC Markets on January 21, 2026. Its annual report for the year ended September 30, 2025 includes a going concern warning.
UMEWNasdaq's staff found only conditional compliance with the $2.5 million equity rule after a December 2025 deficiency notice. The company's auditors had already raised going-concern doubt in its 2024 annual report.
GRINasdaq said NRX Pharmaceuticals is out of compliance because it did not hold an annual meeting within twelve months of fiscal year end. The company set the 2025 Annual Meeting for March 23, 2026.
NRXPPolaryx's 1-for-4 reverse split took effect on January 12, 2026, ahead of a Nasdaq direct listing that raised no money for the company.
PLYXPropanc Biopharma received a Nasdaq notice that its stock has been below the $1.00 minimum bid price, and it has until June 30, 2026 to regain compliance. Its latest annual report showed cash of $12,088 at June 30, 2025.
PPCBNasdaq approved Immunic's move from the Global Select Market to the Capital Market, with trading there from January 7, 2026. The company now has until June 22, 2026 to regain compliance with the $1.00 minimum bid price and has told Nasdaq it would seek a reverse stock split if necessary.
IMUXNasdaq said on December 31, 2025 that the company missed the $1.00 minimum bid price and gets no grace period. Suspension is set for January 9, 2026 unless it appeals by January 7, 2026.
DCOYNasdaq staff plans to delist FibroBiologics after its stock did not regain the $1.00 minimum bid price by December 29, 2025. The company will ask for a hearing and has asked stockholders to approve a reverse split of 1 for 5 to 1 for 30.
FBLGThe January 2, 2026 filing covers the company's common shares. It relies on the SEC rule for a voluntary withdrawal by the issuer.
HELPCommon stock authorized rises from 1,700,000,000 to 2,600,000,000 shares. The company filed the amendment in Delaware on December 30, 2025.
NWBOSilo Pharma did not regain the $1.00 minimum bid price by December 24, 2025, and Nasdaq granted it a second 180-day period to June 22, 2026. The company has told Nasdaq it may use a reverse stock split to cure the deficiency, and its annual report shows an accumulated deficit of $15,264,691.
SILOAnebulo's board dropped a planned reverse split and will instead tender for up to 300,000 shares at $3.50, to keep its holder count below 300 for a go-private plan, while its lead drug rests on a Phase 2 study in healthy volunteers.
ANEBApollomics reports a $4,398 thousand shareholders' deficit at June 30, 2025, after cash fell to $2,094 thousand from $9,766 thousand at year-end and the six months produced a $12,536 thousand loss.
APLMNYSE American accepted Azitra's plan to restore its $4.0 million minimum stockholders' equity and set April 1, 2027 as the deadline. The stock stays listed while the plan runs, but the company's 2024 annual report carried a going-concern warning.
AZTRTherapeuticsMD stockholders approved raising authorized common stock to 640,000,000 shares at the December 15, 2025 annual meeting. The company had 11,574,362 shares outstanding at the record date, and the increase drew 548,884 votes against.
TXMDNasdaq told PharmaCyte on December 1, 2025 that its stock had failed the $1.00 minimum bid price over 30 consecutive business days. The company has until June 1, 2026, and any reverse stock split would need shareholder approval. The filings give no share price or cash figure to show how far the company is from compliance.
PMCBNasdaq gave Intensity until June 1, 2026 to restore a $1.00 closing bid price. The company says it may use a reverse stock split, and the notice has no immediate effect on its listing.
INTSExpected gross proceeds are about $4.97 million. The company says the price is a premium to the Nasdaq Minimum Price.
PLRZNasdaq told GRI Bio on November 26, 2025 that it does not meet the $2,500,000 stockholders' equity requirement for the Capital Market. The company has until January 10, 2026 to submit a compliance plan, and its annual report already carried a going-concern warning.
GRINasdaq told GT Biopharma on November 20, 2025 that its stock had closed below $1 for 30 consecutive business days. The company has until May 19, 2026 to regain compliance, and its last annual report carried a going-concern warning alongside a $13.2 million net loss.
GTBPNasdaq told Akari Therapeutics on November 24, 2025 that its American Depositary Shares had closed below $1.00 for 30 consecutive business days. The company has until May 25, 2026 to regain compliance, and its 2024 annual report carries a going-concern warning.
AKTXMetaVia Inc. (Nasdaq: MTVA) was granted more time to regain compliance after its stock closed below $1.00 for 30 consecutive trading days. It says a reverse stock split is an option.
MTVANasdaq's staff ruled that Artelo had not completed the capital raise it promised to fix its equity shortfall. Trading continues pending a hearing panel appeal, and the company's last annual report carried going-concern doubt.
ARTLNasdaq staff issued a delisting determination against Moleculin Biotech's common stock for failing the $2.5 million stockholders' equity rule. The company said it will ask a hearing panel to stay any suspension, and its last annual report showed $4.3 million of cash and a going-concern warning.
MBRXNasdaq told Soligenix on November 18, 2025 that the matter is closed. The company reported stockholders' equity of $7,597,976 for the quarter ended September 30, 2025, against a $2,500,000 requirement.
SNGXShuttle reported stockholders' equity of $1,394,161 against Nasdaq's $2,500,000 minimum. Nasdaq staff will keep monitoring, and delisting is possible if compliance is not shown in the next periodic report.
SHPHCOSCIENS plans to file a Form 15-F to end its U.S. reporting and has applied for OTCQB quotation. It had $8.5 million of cash on September 30, 2025, and its net loss narrowed to $1.8 million in the quarter.
CSCILunai Bioworks received a Nasdaq notice that its market value of listed securities had been below the $35 million minimum for 30 consecutive business days. It has until April 27, 2026 to regain compliance, and the company says the notice has no immediate effect on trading.
LNAINasdaq said Enveric's stock closed below $1.00 for 30 consecutive trading days and the company has no compliance period. It plans to request a hearing and will split its shares 1-for-12 on October 28, 2025.
ENVBNYSE American told Oragenics on October 20, 2025 that it again meets stockholders' equity standards. The company also paid Ladenburg Thalmann $700,000 to settle a dispute over a $2,500,000 fee claim.
OGENNasdaq says Aspire's shares face delisting for missing the $50,000,000 market value rule and the $1.00 bid price rule. The company paid $20,000 to request a hearing, and its 2024 audit carried going-concern doubt.
ASBPA Nasdaq Hearings Panel granted HCW Biologics (Nasdaq: HCWB) continued listing on October 13, 2025. The company must show compliance with the Equity Rule by December 31, 2025 and with all other rules by February 16, 2026.
HCWBThe plan was amended by the board on October 15, 2025 and is filed as an exhibit. It is built around Nasdaq's inducement-grant exemption from shareholder approval.
KURANasdaq granted Adicet Bio an additional 180 calendar days. The stock moves from the Nasdaq Global Market to the Nasdaq Capital Market on October 9, 2025.
ACETSalarius said $2.4 million from an at-the-market program and $3.8 million from C/M Capital Master Fund, LP lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The figure is preliminary, and Nasdaq has not yet confirmed compliance.
DCOYThe death of director Dr. Alon Lazarus on September 30, 2025 left Werewolf's audit committee with two members, one short of Nasdaq's three-member minimum. The company plans to appoint an independent director at its earliest opportunity.
HOWLThe Nasdaq Stock Market LLC filed the notice with the SEC on October 6, 2025, citing the rule an exchange uses to remove a security.
ZVSAXilio moved its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market after missing the $1.00 minimum bid price. The move does not cure the bid price problem, and the company's March annual report carried a going-concern warning.
XLONYSE American told Azitra on October 1, 2025 that its stockholders' equity of $2.2 million is below the $4.0 million required. The company has until October 31, 2025 to submit a plan, with compliance due by April 1, 2027. Its 2024 annual report carried a going-concern warning.
AZTRNasdaq told Abpro on September 30, 2025 that it had not regained compliance with the $1.00 minimum bid price. The company says it will ask an appeal panel for a hearing, which would stay the suspension, but the filing gives no assurance the panel will grant it more time.
ABPONYSE American says Azitra is below its $4 million stockholders' equity standard, and the company has until October 31, 2025 to file a plan to restore compliance.
AZTRNasdaq approved the transfer from the Global Select Market effective October 6, 2025. Xilio now has until March 30, 2026 to regain compliance with the minimum bid price rule.
XLONasdaq staff told BioCardia in writing that it again meets the Equity Rule, but the 8-K gives no equity figure and does not say how the gap was closed.
BCDABon Natural Life's unaudited interim statements for the six months to March 31, 2025, filed in a Form 6-K on September 29, 2025, reflect a 1-for-25 share consolidation and net proceeds of $10,543,805 from a public offering of Class A ordinary shares. Cash rose from $80,466 to $8,894,053 over the period.
BONNasdaq sent two letters on September 23, 2025 closing both matters. The company had been notified of the deficiencies in April and August.
ESLANasdaq told Tevogen Bio Holdings on September 23, 2025 that its shares had closed below $1.00 for 30 consecutive business days, giving it until March 23, 2026 to regain compliance. Its 2024 annual report said the company was relying on $8.0 million of grant funding it had not yet received.
TVGNNasdaq notified Longeveron (LGVN) on September 22, 2025 that its Class A common stock missed the $1.00 minimum bid price. The notice does not cause immediate delisting; a second 180-day period may be available.
LGVNA Nasdaq Hearings Panel gave Adaptimmune until December 1, 2025 to meet the $1.00 minimum bid price, or its American Depositary Shares will be delisted. The 8-K gives no share price and no count of days below the floor.
ADAPYThe company has until March 23, 2026 to bring its Class A common stock back above the threshold. The notice has no immediate effect on its listing.
LGVNNasdaq's September 23, 2025 letter confirmed that Silexion meets its $2.5 million shareholders' equity rule and its $1.00 bid-price rule. The company is now under a mandatory panel monitor until September 23, 2026, and one more equity failure in that period would lead to a delisting determination.
SLXNBioCardia says its stockholders' equity exceeds the $2.5 million Nasdaq minimum after two private placements, an offering with net proceeds of about $5.1 million and at-the-market sales. Nasdaq will keep monitoring the company.
BCDAA Nasdaq hearing panel let BioAtla stay listed on conditions: a transfer to the Nasdaq Capital Market by September 26, 2025, equity compliance by December 31, 2025 and bid price compliance by February 2, 2026.
BCABNasdaq told Prelude on September 18, 2025 that the bid-price matter is closed. The company had been out of compliance since a March 27, 2025 notice.
PRLDNasdaq told Vaxart on September 19, 2025 that its common stock will be delisted after the company withdrew a reverse stock split proposal that a hearings panel had made a condition of continued listing. Trading on Nasdaq was suspended on July 8, 2025.
VXRTNasdaq told ZyVersa it would announce the delisting on September 18, 2025. The shares have traded on the OTCQB Venture Market since July 28, 2025.
ZVSAAquaBounty told the SEC on September 17, 2025 that Nasdaq closed its $1.00 bid price matter after a January 15, 2025 notice. The company no longer runs any salmon farm, and its 10-K puts 2024 impairments at $129.8 million.
AQBNasdaq accepted Neuphoria's plan on September 10, 2025, after a July 18, 2025 notice that it had not held an annual meeting. The company has until December 29, 2025 and says it will file its Form 10-K on or before September 29, 2025.
NEUPNasdaq says the 6% Convertible Exchangeable Preferred Stock has been below the $1 million minimum for publicly held shares for 30 consecutive business days. The company has until March 10, 2026 to regain compliance, and its 8-K does not say how it will get there.
BGMSNasdaq told Ovid on September 11, 2025 that it again meets the $1.00 minimum bid price, but the company's notice does not say how it got back above that level.
OVIDRelmada Therapeutics said on September 16, 2025 that Nasdaq confirmed in a September 15 notice that it has regained compliance with the $1.00 minimum bid price. The stock stays on the Nasdaq Capital Market under RLMD, but the company's lead drug failed in late 2024.
RLMDNasdaq told the company on September 11, 2025 that its stock closed below $1.00 for 30 consecutive business days. It has until March 10, 2026 to regain compliance, and the Nasdaq Capital Market listing is unchanged for now.
YARWNasdaq confirmed the matter is closed after Pluri elected Eitan Ajchenbaum as an independent director and Audit Committee chair. The gap began after the June 30, 2025 annual meeting.
PLURVYNE Therapeutics, now Yarrow Bioscience, has until March 10, 2026 to lift its closing bid price back to at least $1.00 per share.
YARWThe company has until March 4, 2026 to regain compliance with the minimum bid price rule. Its shares keep trading on The Nasdaq Capital Market for now.
OSRHNasdaq closed the matter on September 5, 2025, ahead of the December 29, 2025 deadline the company had been given.
CHRSThe company says Nasdaq closed its listing matter and that its cash lasts into 2029. The release gives no cash balance or burn figure and does not say what steps restored compliance.
NCNANasdaq staff set a September 8, 2025 delisting date. CERo requested a hearing on September 3, 2025, which stays the suspension, and plans to present a compliance plan.
CERONasdaq notified the company on August 29, 2025. Its shares closed at $1.00 or more for at least 10 consecutive business days.
EQThe notes carry a 5% coupon and convert at US$16.25 per ADR. Issuance depends on shareholder approval at the upcoming annual general meeting.
MSBAdial Pharmaceuticals has until March 2, 2026 to hold its shares at $1.00 or more for ten consecutive business days. Its 10-K for 2024 said current cash would not cover the next twelve months, and its accumulated deficit reached $82.0 million.
ADILNasdaq told Celularity on September 2, 2025 that it complies with Listing Rule 5250(c)(1) again, after the company filed its Form 10-Q reports for the periods ended March 31 and June 30, 2025.
CELUNasdaq told Ironwood on August 29, 2025 that the matter is closed. The company had received a deficiency notice on May 28, 2025.
IRWDNasdaq gave Context Therapeutics until February 23, 2026 to regain compliance with the $1.00 minimum bid price rule. The company says it may need a reverse stock split and cannot promise it will regain compliance.
CNTXThe new deadline is February 23, 2026. The company says a reverse stock split is an option if needed, and it gives no assurance it will regain compliance by then.
CNTXNasdaq said Envoy did not regain compliance with its $35,000,000 market value of listed securities requirement. A hearing request filed August 29, 2025 stays any trading suspension.
COCHNasdaq says Enveric does not meet the $2,500,000 minimum stockholders' equity requirement. The company reported stockholders' equity of $2,184,769 in its latest 10-Q and has until October 10, 2025 to file a compliance plan.
ENVBNasdaq's deficiency letter came after the company reported stockholders' equity of $2,184,769 at June 30, 2025, below the $2,500,000 minimum for the Nasdaq Capital Market. Enveric has until October 10, 2025 to submit a plan to regain compliance.
ENVBNasdaq gave Century until February 23, 2026, to lift its closing bid price above $1.00, and moved its listing to the Nasdaq Capital Market. The company's own clinical data for its lead lymphoma program did not meet its bar for a transformational result.
IPSCRallybio moved its listing to the Nasdaq Capital Market on August 29, 2025 after missing its first bid-price deadline. It received 180 more days, to February 23, 2026, to bring its stock back to at least $1.00.
RLYBNasdaq says Xilio reported stockholders' equity of $7,069,000 at June 30, 2025, below the $10.0 million minimum for the Global Select Market. The company has until October 6, 2025 to submit a plan, and it remains out of compliance with the $1.00 minimum bid price rule.
XLOImunon (Nasdaq: IMNN) says the Nasdaq Hearings Panel notified it on August 27, 2025 that it meets the $1.00 minimum closing bid price. The stock will continue trading on the Nasdaq Capital Market.
IMNNThe Nasdaq Hearings Panel confirmed compliance, so Imunon common stock will keep trading on The Nasdaq Capital Market. The company also pointed to a recent 15% stock dividend.
IMNNA Nasdaq letter received August 26, 2025 says Veru has regained compliance with the $1.00 minimum bid price rule and that the matter is closed. Nasdaq first wrote to the company about the bid price on August 29, 2024.
VERUBriaCell's board approved a one-for-ten share consolidation to keep its Nasdaq listing, expected to take effect August 25, 2025, subject to approval from Nasdaq and the Toronto Stock Exchange.
BCTBCTXNasdaq told Cognition Therapeutics on August 26, 2025 that the company again meets its listing requirements after the stock closed above $1.00 for more than ten trading days.
CGTXNasdaq confirmed compliance with both the $35 million market value standard and the $2.5 million equity standard. The bid price deadline moves to November 12, 2025.
CNSYCOSCIENS marked the voluntary withdrawal box on its Nasdaq Form 25. The form gives no reason, and the company's April 2025 annual report describes a failed Phase 3 trial and a shift to natural-based products.
CSCILiminatus Pharma (Nasdaq: LIMN) has until October 21, 2025 to submit a plan to regain compliance after the delayed filing of its report for the period ended June 30, 2025. The stock keeps trading for now.
LIMNNasdaq staff told Dermata on August 22, 2025 that the company again meets the $1.00 minimum bid price, which closes the matter. The company needed a hearing panel's exception to reach that point, and its 8-K gives no cash figure.
DRMANasdaq staff said Curis did not regain compliance with the $35,000,000 market value requirement by August 20, 2025. Curis must request a hearing by August 28, 2025; the request keeps its stock listed during the appeal.
CRISCuris missed Nasdaq's $35 million market value rule and must ask for a hearing by August 28, 2025 to avoid delisting. It says it will ask, and its shares stay listed while a panel decides.
CRISThe new deadline is February 17, 2026. Atossa said it may consider a reverse stock split if needed.
ATOSNasdaq says Genprex's equity of $1,391,195 is below the $2.5 million minimum, adding a second basis for delisting to an unresolved bid price failure. A hearing request has stayed any delisting for now.
GNPXNasdaq will suspend trading in Windtree's common stock at the open on August 21, 2025. The company has applied for the OTCID tier.
WINTNasdaq says HCW Biologics was out of compliance with its equity rule on June 30, 2025. The shares would be suspended on August 28 unless the company asks for a hearing by August 26.
HCWBStockholders' equity of $1,391,195 at June 30, 2025 is below the $2.5 million minimum. Genprex has asked for a Nasdaq Hearings Panel hearing, which pauses any delisting while the process runs.
GNPXSol-Gel's second-quarter report shows $24.2 million in cash and securities at June 30, 2025, and net income of $11.6 million that came mostly from a one-time $16 million sale of U.S. product rights. The company's largest pipeline asset still has no results until the fourth quarter of 2026.
SLGLSoligenix reported stockholders' equity of $1,828,951 at June 30, 2025 and has until September 29, 2025 to submit a plan to regain compliance with the Nasdaq minimum.
SNGXNasdaq said on August 8, 2025 that Intensity meets the $2,500,000 stockholders' equity requirement. That finding rests partly on share sales made in July, and the company could still face delisting if its next periodic report does not show compliance.
INTSVeru's 1-for-10 reverse stock split took effect at 11:59 p.m. Central time on August 8, 2025, and the stock trades split-adjusted from August 11. The 8-K gives no reason for the split and no pre-split share count.
VERUVerrica's 1-for-10 reverse stock split took effect at the close of trading on July 24, 2025, cutting issued shares from 92,650,404 to 9,265,034. Second-quarter net income of $0.2 million depended on an $8.0 million Torii milestone.
VRCAFibroBiologics received a Nasdaq notice that its market value of listed securities is below the $35.0 million minimum. It has until February 2, 2026 to close at or above that level for ten business days, and the 8-K gives no current market value or remedy.
FBLGNasdaq has given Processa until February 2, 2026 to bring its share price back to at least $1, a second 180-day period. The company says it will consider a reverse stock split, and the filing gives no recent share price to show how far it is from the threshold.
PCSANasdaq told Estrella on August 1, 2025 that its market value of listed securities fell below the $35,000,000 minimum. It has until January 28, 2026 to regain compliance, and its annual report for the year ended June 30, 2024 carried a going-concern warning.
ESLABon Natural Life says Nasdaq has closed its bid price matter after the Hearings Panel decision, but the company stays under a one-year Discretionary Panel Monitor. The Nasdaq confirmation came on July 29, 2025, and the company reported it in a Form 6-K dated August 4, 2025.
BONNasdaq's board declined to review a May 15, 2025 Listing Council decision, making it Nasdaq's final action. The company's chief financial officer and a director have also resigned.
OCEAExicure said it met Listing Rule 5250(c)(1) as of July 1, 2025, after filing its Form 10-Q for the quarter ended March 31, 2025.
XCURGeoVax's closing bid price was below $1.00 for 30 consecutive business days, according to a July 31, 2025 deficiency letter. The first deadline is January 27, 2026, and a second 180-day period is possible.
GOVXThe company has until January 26, 2026 to regain compliance. Its shares keep trading on The Nasdaq Capital Market under the symbol IBIO for now.
IBIOThe exchange suspended trading in the company's $184.00 warrants because of their low trading price. The common stock is not affected.
EDVARevenue was $24.5 million in both fiscal 2025 and fiscal 2024, and the net loss widened to $30.2 million from $26.1 million. The release gives no date for the regained Nasdaq compliance.
HYFTOcugen's stock closed at or above $1.00 for ten business days from July 8, 2025 to July 25, 2025. Nasdaq said on July 28, 2025, that the matter is closed.
OCGNNasdaq confirmed on July 28, 2025 that Passage Bio's shares had closed at $1.00 or more for at least 10 consecutive business days, closing a matter that began in August 2024.
PASGThe stock closed below $1.00 for 32 consecutive business days. Shares keep trading on the Nasdaq Capital Market under ADVB during the compliance period.
ADVBNeuphoria Therapeutics received a Nasdaq notice that it did not hold an annual meeting within a year of its June 30, 2024 fiscal year end. It has until September 1, 2025 to submit a plan, and its annual report for that year carries a going-concern warning with cash that, combined with an ATM facility, is expected to fund work into late in the first quarter of fiscal 2026.
NEUPThe Nasdaq Stock Market LLC filed a Form 25-NSE on July 18, 2025, to remove Avenue Therapeutics common stock from listing and registration.
ATXIThe company's American Depositary Shares closed at $1.00 or more for 10 straight business days, ending a deficiency first flagged on March 24, 2025.
CNTBCell Source's July 16, 2025 Form 15 checked the rule for suspending reporting duties. Its later filing list shows more reports, and in January 2026 the company said it was preparing a Nasdaq uplist.
CLCSThe stock closed at $1.00 or higher for 10 consecutive business days from June 27, 2025 to July 11, 2025. Nasdaq considers the matter closed.
INDPThe panel granted the exception on July 11, 2025, so Imunon can regain compliance with the $1.00 minimum bid price and the stockholders' equity requirement. Stockholders also approved 2,000,000 more plan shares, bringing the plan's limit to 3,970,000.
IMNNNasdaq Stock Market LLC filed a Form 25 notification dated July 11, 2025 to strike Bio-Path Holdings' common stock from listing and registration. The notice cites Exchange Act Rule 12d2-2(b), which covers removals the exchange initiates, and it does not give the reason.
BPTHNasdaq confirmed on July 9, 2025 that Jupiter's stock held an average closing price of at least $1.00 over 13 days. The company's last annual report still carries a going concern warning.
JUNSVor Bio appointed Sandy Mahatme as chief financial officer and chief business officer effective July 9, 2025, and granted him 13,882,750 restricted stock units under Nasdaq's inducement rule. The release gives no share count or grant value to compare that award with.
VORNasdaq staff found the stock closed at $1.00 or more for 10 consecutive business days, from June 17, 2025 to July 1, 2025.
FTHNasdaq closed the matter on July 3, 2025, after the company held its annual meeting on June 30, 2025. The April annual report said the planned rescission of the ImmunogenX merger needed shareholder approval.
GRDXNasdaq confirmed on July 7, 2025 that Unicycive's shares had averaged at least $1.00 after a 1:10 reverse stock split took effect on June 20, 2025. The release does not say what the FDA has done on the company's lead candidate, which had a PDUFA date of June 28, 2025.
UNCYProMIS now has until December 29, 2025 to lift its share price to at least $1.00. It said it may effect a reverse stock split if necessary.
PMNNasdaq told Coherus on June 30, 2025 that its stock had closed below $1.00 for 30 consecutive business days. The company has until December 29, 2025 to regain compliance, while its cash, cash equivalents and marketable securities were $126.0 million at December 31, 2024 against $230.0 million of 2026 convertible notes.
CHRSPluri told Nasdaq it fell below the three-independent-director minimum for its audit committee after shareholders voted against director Doron Birger, who chaired it. The cure period ends no later than June 30, 2026, and the company says it will add an independent director.
PLURNasdaq notified Silo Pharma on June 27, 2025 that its common stock has not met the $1.00 minimum bid price. The company has until December 24, 2025 to regain compliance, and may consider a reverse stock split if needed.
SILOLexicon gets until December 30, 2025 to regain the $1 minimum bid price and moves to the Nasdaq Capital Market on July 7, 2025, with a reverse split on the table if needed.
LXRXNasdaq told Silo Pharma on June 27, 2025 that its common stock fell below the $1.00 minimum bid price, based on closing bids from May 14 to June 26. The company has until December 24, 2025 to regain compliance and says it may consider a reverse stock split.
SILOAlaunos told Nasdaq on July 2, 2025 that its audit committee falls short of Listing Rule 5605(c). The shortfall came after chief executive Dale Curtis Hogue, Jr. resigned and director Holger Weis took over as CEO and left the committee. The company plans to use a 180-day grace period.
TCRTNasdaq granted Ocugen (Nasdaq: OCGN) an additional 180 calendar days to regain compliance with the $1.00 minimum closing bid price requirement. The first period ended June 30, 2025.
OCGNAptevo says about $15.9 million of gross equity raised in the June quarter puts it back above Nasdaq's $2.5 million stockholders' equity minimum. The figure is the company's own belief, and it was still awaiting formal confirmation from Nasdaq.
APVONasdaq notified IN8bio on June 24, 2025 that the company again meets Listing Rule 5550(a)(2). The exchange said the matter is now closed.
INABThe company has until December 24, 2025 to regain compliance. The notice has no immediate effect on its listing on The Nasdaq Global Select Market.
IMUXThe company has until December 22, 2025 to regain compliance. It may qualify for a second 180-day period and is considering its options.
KTTAThe stock closed below $1.00 for 30 straight business days. The company may consider a reverse stock split to regain compliance.
MBRXNasdaq told Nektar on June 24, 2025 that it met the minimum bid rule after a $1.00 closing bid held for 10 consecutive business days. The 8-K gives no share price or financial figures, and the company's pipeline is still in mid-stage trials.
NKTRSCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.
SCYXNasdaq says Bone Biologics has met the $1.00 bid price rule after a 10-day run, but the release gives no share price, and its lead product still needs FDA approval before sale.
BBLGRani Therapeutics received a Nasdaq notice on June 20, 2025 that its Class A shares had a closing bid price below $1.00 for 30 consecutive business days. Its deadline to regain compliance is December 17, 2025, and the notice gives no closing price.
RANISCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.
SCYXLipella's common stock was quoted on the OTC Pink Market under LIPO as of June 19, 2025. Nasdaq objected to securities paid to a placement agent and advisor.
LIPOSutro has until December 17, 2025 to bring its share price back above $1.00 for ten consecutive business days, or face a delisting process. The company says it plans a reverse stock split before that date if necessary, and its 10-K shows three partners that ended clinical work after Phase 1.
STROCaribou's Nasdaq notice covers a window of about two weeks, from June 3 to June 17, 2025, when its closing bid was $1.00 or more. The 8-K does not say what the price did before or after that window.
CRBUAIM ImmunoTech had a stockholders' deficit of negative $3.9 million at March 31, 2025, and its 2024 net loss was approximately $17,320,000. Its tax-loss sales are capped, and the exchange deadline to fix the deficit is June 11, 2026.
AIMThe NYSE accepted Annovis Bio's plan to regain compliance with its market capitalization and stockholders' equity standards, giving the company 18 months from a March 26, 2025 notice, quarterly progress reports and a warning that trading could still be suspended.
ANVSStockholders voted 39,547,136 for and 20,664,896 against the increase, with 95,178 abstentions. The company filed the amendment in Delaware the same day.
CCCCReShape says sales under its at-the-market program and a June 9 offering have lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The company says that does not guarantee it will stay listed.
HINDBioNTech and CureVac signed a purchase agreement dated June 12, 2025 for a share exchange offer. The number of BioNTech shares per CureVac share moves with BioNTech's price, and the offer depends on a minimum condition.
BNTXNasdaq extended Equillium's deadline to December 8, 2025. The company says it will consider options including a reverse stock split, and its stock keeps trading on the Nasdaq Capital Market as "EQ".
EQThe transfer from the Nasdaq Global Market is part of the company's effort to meet Nasdaq continued listing requirements. Shares would keep trading as IXHL.
IXHLAIM ImmunoTech regained NYSE American compliance on its low selling price test after a 1-for-100 reverse split effective June 12, 2025, with trading under AIM due to resume June 17. Its 2024 annual report carries a going-concern warning and a working capital deficit, and a separate stockholders' equity notice from December 2024 is not covered by this filing.
AIMA Nasdaq panel accepted Spruce Biosciences' appeal, but the stock returns to the Capital Market only if it meets the minimum bid price by August 5, 2025. Trading had been suspended on April 29, 2025, and the 10-K carries a going-concern warning.
SPRBNasdaq notified the company on June 11, 2025. Its American Depositary Shares will stay listed and traded on Nasdaq.
NBPSpruce's shares have traded over the counter since a Nasdaq suspension on April 29, 2025. The Hearings Panel accepted the company's appeal on June 9, 2025, but the stock returns to the Nasdaq Capital Market only if it meets the bid price requirement by August 5, 2025.
SPRBBolt Biotherapeutics filed a one-for-twenty reverse stock split on June 6, 2025, with split-adjusted trading set for June 9. The 8-K gives no reason for the split, and the company's 2024 annual report already said there was substantial doubt about its ability to continue as a going concern.
BOLTBolt Biotherapeutics filed a Certificate of Amendment on June 6, 2025 to effect a one-for-twenty reverse stock split. Split-adjusted trading on the Nasdaq Capital Market under the existing ticker BOLT was scheduled to begin June 9, 2025, under a new CUSIP number.
BOLTCommon stock authorized rises from 200,000,000 shares. The vote was 85,825,060 for and 11,001,501 against, and the 8-K gives no reason for the larger share count.
TNGXTalphera (TLPH) moved its listing to The Nasdaq Capital Market on May 30, 2025 and received an additional 180 days to regain the $1.00 minimum bid price. It has told Nasdaq it will use a reverse stock split, if necessary.
TLPHTalphera moved its stock to the Nasdaq Capital Market on May 30, 2025 to qualify. It told Nasdaq it would do a reverse stock split if necessary.
TLPHNektar's board approved the split on May 23, 2025, and trading on a split-adjusted basis is set to begin June 9. The filings give no reason for the split, and a June 6 amendment raised authorized shares to 390,000,000.
NKTRNasdaq said Ironwood's Class A stock closed below $1.00 for 30 consecutive business days. The company has until November 24, 2025 to regain compliance, and the letter has no immediate effect on its listing.
IRWDCommon stock authorized rises from 400,000,000 shares. The company filed the amendment in Delaware on June 2, 2025.
TSHAThe amended charter also lifts total authorized capital stock to 395,000,000 shares. Holders also approved a revised 2015 Stock Incentive Plan that removes its evergreen provision.
EDITThe company's stock closed below $1.00 for 30 consecutive business days. It may be eligible for a second period of 180 calendar days.
MTVANasdaq closed the matter on May 27, 2025, after the stock closed at $1.00 or above for 10 consecutive trading days. The annual report put the lead programs in Phase 1, and the 8-K gives no cash figures.
CTMXMindMed named Brandi L. Roberts chief financial officer effective June 2, 2025, with inducement awards of an option on 500,000 shares and 125,000 performance share units. The awards sit outside the company's equity plans, and the lead drug's pivotal trials have not yet reported.
DFTXThe May 22, 2025 letter cites Nasdaq Listing Rule 5550(b)(1). Artelo has until July 7, 2025 to submit a plan to regain compliance, and the stock stays listed in the meantime.
ARTLNasdaq notified the company on May 21, 2025 that its late quarterly report breaks Listing Rule 5250(c)(1). It must submit an update to its compliance plan by July 21, 2025, and any exception could run until November 17, 2025.
CNSYBiofrontera reported stockholders' equity of $469,000 at March 31, 2025, far below the $2,500,000 Nasdaq requires. It has 45 calendar days to submit a plan to regain compliance.
BFRIThe minimum stockholders' equity requirement is $2.5 million. Q32 Bio has 45 calendar days to submit a plan to regain compliance.
QTTBNasdaq flagged the missing quarterly report on May 20, 2025 as another basis for delisting, ahead of a Panel hearing set for May 27, 2025. Onconetix also issued a promissory note to Keystone Capital Partners for a $250,000.00 purchase price.
ONCOAptevo reported a stockholders' deficit of $1,473,000 against a $2,500,000 minimum. It also filed an at-the-market prospectus supplement for up to $3,015,515 of stock, and it set a 1-for-20 reverse stock split for May 23, 2025.
APVONasdaq confirmed on May 22, 2025 that the bid price deficiency matter is closed. The stock closed at $1.00 or more for 13 consecutive business days.
SLGLA Nasdaq Hearings Panel has decided to delist Petros, with trading suspended at the open on May 22, 2025, on four grounds that include equity and bid-price rules and concern over the February 2025 public offering. Petros will ask the Listing Council to review the decision.
PTPINasdaq says the company, whose cash was $2,590 thousand at year-end 2024, fell short of the $2,500,000 stockholders' equity minimum and has until July 3, 2025 to submit a compliance plan.
INTSDermata said on May 16, 2025 that Nasdaq's staff has confirmed it regained compliance with the stockholders' equity requirement, but a bid price notice says its securities will be suspended on May 23, 2025 unless it requests a hearing by May 21. The company plans to request one.
DRMANasdaq told Neumora Therapeutics on May 14, 2025 that it is below the $1.00 minimum bid price requirement. The company is weighing a reverse stock split, with a stockholder vote set for May 28, 2025.
NMRAThe company has until November 10, 2025 to regain compliance. Stockholders vote on a possible reverse stock split on May 28, 2025.
NMRATivic reported $669,000 of cash at March 31, 2025 and a $1.5 million net loss for the quarter. It then lined up a $25 million equity line and a purchase agreement for up to $8.4 million of securities.
VBIOSangamo's underwritten offering is expected to bring in about $23.0 million. The 46,633,393 purchase warrants in the deal outnumber the 12,235,000 common shares, and Cantor Fitzgerald & Co. represents the underwriters.
SGMOQNasdaq's hearings panel decided to delist Hepion after it failed the $1.00 minimum bid price and Nasdaq said it believes the company is a public shell. Trading was set to stop on May 13, 2025, and Hepion expects its shares to quote on the OTC Markets.
HEPAImmunome's cash total includes $161.7 million from a January 2025 financing, and the quarter ended with a $41.6 million net loss. Its lead drug's Phase 3 data are not due until the second half of 2025.
IMNMNasdaq gave the company until November 3, 2025 to lift its bid above $1.00 for 10 straight business days. The first 180-day period expired on May 5, 2025, and the release gives no plan beyond the CEO's stated confidence.
COSMTransCode received a Nasdaq notice on May 6, 2025 that its stock would be delisted from the Nasdaq Capital Market unless it appeals. Earlier reverse splits left it with no compliance period, so it must request a hearing by May 13, 2025.
RNAZPalisade Bio received a Nasdaq minimum bid price notice on April 30, 2025, after its stock closed below $1.00 for 30 consecutive trading days. It has 180 calendar days to regain compliance, and its 2024 annual report carries a going-concern warning alongside $9.8 million of cash.
PALIPalisade Bio has 180 calendar days from an April 30, 2025 Nasdaq notice to get its shares back above $1.00, and its lead candidate is still in a Phase 1 study.
PALIThe audit opinion in Armata's 2024 annual report contains a going concern explanatory paragraph. The company also received $4.65 million of additional Department of Defense award funding.
ARMPABVC reported stockholders' equity of $723,959, below the $2,500,000 Nasdaq minimum. It also sold shares to 15 non-U.S. buyers for a little more than $436,000.
ABVCNasdaq said on April 29, 2025 that Quoin's ADSs closed at $1.00 or more from April 9 to April 28, closing the minimum bid price matter. The company says it has no commercialized product and has generated no revenue to date.
QNRXScilex met the $1.00 minimum closing bid price requirement on April 30, 2025. Its common stock and public warrants stay on the Nasdaq Capital Market.
SCLXNasdaq confirmed on April 29, 2025 that the stock averaged at least $1.00 over 10 consecutive business days. Amarin will stay listed on Nasdaq.
AMRNNasdaq sent the company a formal notice of compliance on April 24, 2025. The 8-K does not say how the price was restored, and the lead drug's Phase 3 timeline is subject to funding.
TPSTNasdaq says the stock's bid price was below $1.00 for 30 consecutive business days and, after a recent reverse stock split, no compliance period applies. The company plans to appeal by April 30, 2025.
DCOYNasdaq told Incannex on April 23, 2025 that its shares had closed below $1.00 for 30 consecutive trading days, giving it until October 20, 2025 to regain compliance. Its annual report for the year ended June 30, 2024 carries an auditor's going concern paragraph.
IXHLNasdaq will suspend trading on April 29, 2025, and the company's appeal will not stop it. The company is cutting 55% of staff to focus on a rare-disease therapy it has not yet filed for approval, with going-concern doubt on record.
SPRBNYSE American accepted AEON Biopharma's plan to regain compliance with three continued listing standards and gave the company until August 3, 2026. The 8-K does not say which financial measures the company missed, and the company's migraine trials failed their primary endpoints.
AEONOne letter cites the $50,000,000 market value of listed securities rule, with a deadline of October 13, 2025. The other cites the $1.00 minimum bid price rule.
ASBPTenaya has until October 13, 2025 to regain compliance, and may get another 180 days if it moves to the Nasdaq Capital Market.
TNYANasdaq found PainReform complies with Rule 5550(b)(1), but warned that delisting could follow if the next periodic report does not show compliance.
PRFXNasdaq's hearings panel has decided to delist Aspira Women's Health, which says its shares will trade on OTC markets under the symbol AWH.
AWHLThe transfer takes effect April 17, 2025. Athira, now LeonaBio, has until October 13, 2025 to lift its stock to $1.00 and is seeking approval for a reverse split.
LONANasdaq says MIRA's stockholders' equity of $2,199,750 at December 31, 2024 is below the $2.5 million minimum. The company has until May 23, 2025 to submit a plan, and says a pending acquisition would bring a $5 million capital infusion.
MIRANasdaq said the company had not adopted or disclosed a required clawback policy on time, but is now in compliance and the matter is closed.
CELZMIRA reported stockholders' equity of $2,199,750 as of December 31, 2024, below the $2.5 million Nasdaq minimum. It has until May 23, 2025 to submit a plan to regain compliance, and its main fix is an acquisition the release says it expects to complete.
MIRANYSE Regulation said it will start proceedings to delist Palatin Technologies (NYSE American: PTN) after the company did not regain compliance within an 18-month plan period. Palatin intends to appeal.
PTNEach American Depositary Share will represent twenty ordinary shares instead of one. The company says the aim is to meet Nasdaq's $1.00 minimum bid price.
AMRNNasdaq staff said Denali Capital Acquisition Corp. had not regained compliance with its $50.0 million market value and total assets rules and also failed the public float rule. The blank-check company's securities will be delisted unless it appeals by April 9, 2025.
SMNRNYSE American suspended trading in AIM ImmunoTech (NYSE American: AIM) and began delisting proceedings, citing the low selling price of the stock. The company plans to appeal and expects Pink Open Market trading on April 7, 2025.
AIMW. Thorpe McKenzie retired from the board effective March 27, 2025. XBiotech will run one-member audit and compensation committees for now.
XBITDogwood says a $19.9 million debt exchange with Conjoint and a sale of about $4.8 million in common stock lifted its stockholders' equity above the $2.5 million minimum. Nasdaq had set a May 14, 2025 deadline, and the release does not include a Nasdaq decision.
DWTXThe company reported pro forma stockholders' equity of $2.8 million as of March 31, 2025, against a $2.5 million minimum. It also said it meets the market value of publicly held securities rule.
CDTNasdaq told CNS Pharmaceuticals on March 31, 2025 that it meets the $1.00 bid price rule. For one year, a new lapse leads to a delisting determination, with no compliance plan or extra time.
CNSPAcurx Pharmaceuticals received a Nasdaq letter saying it no longer meets the $2,500,000 stockholders' equity minimum for the Capital Market. The company must submit a plan to regain compliance by May 9, 2025, and the notice rests on its 2024 annual report.
ACXPThe NYSE says Annovis's 30-day average market capitalization was approximately $37.9 million and its stockholders' equity was $9.3 million, both under the $50 million floor. The company's 10-K already carries a going-concern warning and says its cash lasts into the fourth quarter of 2025.
ANVSIronwood (Nasdaq: IRWD) has until May 20, 2025, to submit a plan to regain compliance with Nasdaq's timely filing rule and says it plans to file the 2024 Form 10-K as soon as practicable.
IRWDDermata reported stockholders' equity of about $1.6 million against the $2.5 million Nasdaq minimum. It must regain compliance or submit a plan by May 9, 2025.
DRMAJupiter Neurosciences received a Nasdaq letter on March 21, 2025 saying its stock fails the $1.00 minimum bid price rule. The company has until September 17, 2025 to regain compliance.
JUNSNasdaq told TNF Pharmaceuticals on March 17, 2025 that its closing bid price was below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and remains listed on the Nasdaq Capital Market.
QCLSTNF Pharmaceuticals, now Q/C Technologies, has until September 15, 2025 to bring its closing bid price back to $1.00 for ten business days.
QCLSMinerva keeps its Nasdaq listing on a net income test, not an equity test, and now faces a one-year panel monitor. The company reported $21.5 million in cash at the end of 2024 and says it will need more capital.
NERVFibroGen did not regain compliance by March 11, 2025 and appealed a Nasdaq delisting decision on March 14, 2025. The delisting is stayed pending a Hearings Panel ruling.
KYNBThe company failed to meet Nasdaq's $2,500,000 stockholders' equity rule by the panel's deadline. Trading moves to the OTC Markets under the ATXI symbol.
ATXIThe Rochester, New York company filed the notice on March 17, 2025. It covers its common stock, par value $0.0001 per share.
VCNXGelteq cannot sell to Lincoln Park until a resale registration statement is declared effective. The agreement caps issuance at 1,881,328 shares unless shareholders approve more or the average price reaches $1.29.
GELSThe requirement was met on March 12, 2025 after a notice dated January 29, 2025. Nasdaq considers the matter closed.
TLSAShuttle Pharmaceuticals priced 19,166,667 shares, or pre-funded warrants, at $0.30 per share for gross proceeds expected to be about $5.75 million. WestPark Capital, Inc. is the sole book-runner on a firm commitment basis.
SHPHNasdaq told Adial Pharmaceuticals on March 5, 2025 that its stock had closed below $1.00 for 30 consecutive business days. The company has until September 1, 2025 to regain compliance, and its annual report carries a going-concern warning.
ADILNasdaq says the market value of Envoy Medical's listed securities did not meet the minimum for 31 consecutive business days. The company has until August 25, 2025 to regain compliance.
COCHThe company says it is withdrawing its listing voluntarily and has complied with the exchange's rules for doing so.
IBIONasdaq told Curis that its listed securities were worth less than $35,000,000 for 30 consecutive business days. The company has until August 20, 2025 to regain compliance.
CRISNasdaq said CytomX stock did not hold a $1.00 minimum bid for 30 consecutive business days. The company has 180 calendar days to regain compliance, and the notice has no immediate effect on its listing.
CTMXRallybio's closing bid price was below $1.00 for 30 consecutive business days. It may be eligible for another 180-day period if it applies to move its listing to the Nasdaq Capital Market.
RLYBThe company is already before a Nasdaq Hearings Panel over a separate rule, 5550(a)(2). It says it will ask for a stay of the suspension and is working on the report.
UPCNasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until August 20, 2025 to cure, and a second 180-day period is possible.
ATOSPharming's subsidiary now controls 92.70 percent of Abliva through its SEK 0.45 cash offer, and it has extended the acceptance period to March 6, 2025 for holders who have not yet tendered. Pharming plans a compulsory acquisition of the rest and a delisting from Nasdaq Stockholm.
PHARMPHARNasdaq's staff found on February 12, 2025 that Conduit Pharmaceuticals had not met two market value requirements within the 180-day grace period. The next day the company repaid the last $926,149 of a senior secured note to Nirland Limited, which it says was meant to help with the Nasdaq deficiencies.
CDTCitius Pharmaceuticals ended its fiscal first quarter with $1,100,079 in cash, after operations used $4,725,852 and inventory absorbed $6,112,603. The release does not name a placement agent for the offerings it describes.
CTXRCTOREvaxion says it restored stockholders' equity above the $2.5 million minimum and has cash runway into mid-2026. Nasdaq imposed a one-year monitor.
EVAXNasdaq says Ovid's average closing bid price was below $1.00 for 31 consecutive trading days. The company has 180 calendar days to regain compliance and says its Nasdaq listing is unaffected for now.
OVIDNasdaq closed BriaCell's bid price matter on February 12, 2025, after an August 2024 letter cited 30 consecutive business days with closing bids below $1.00.
BCTBCTXNasdaq says Genprex does not meet the $1.00 minimum bid price, based on the last 30 consecutive business days. Separately, Nasdaq extended the company's deadline on the stockholders' equity requirement.
GNPXThe January 21, 2025 agreement sells up to $2,840,000 of shares at $0.20 each, with warrants for 200 percent of each buyer's shares at $1.00. It also sets a penalty of 2.0 percent of the subscription amount for public information failures.
SXTCNasdaq accepted Pluri's compliance plan after a November 25, 2024 deficiency letter. The company must show $2,500,000 in stockholders' equity by the deadline or may face delisting, and its shares keep trading as PLUR.
PLURThe company says stockholders' equity is now about $7.5 million, up from $2.2 million at September 30, 2024. Nasdaq staff will keep monitoring, and the company could face delisting if it cannot show compliance in its next periodic report.
PYPDGain Therapeutics received a Nasdaq deficiency notice on January 8, 2025 over its Market Value of Listed Securities. Nasdaq staff confirmed in writing on January 15 that the company is back in compliance.
GANXEach ADS now represents fifty ordinary shares instead of ten. The company says the change is meant to support liquidity in its ADSs on Nasdaq.
EVAXThe January 6, 2025 letter cites Section 704 of the NYSE American Company Guide. The shares stay listed with a ".BC" indicator, and Matinas says it will hold its annual meeting no later than December 31, 2025.
MTNBIncannex Healthcare received a Nasdaq notice on January 3, 2025 that its market value of listed securities fell below the $50.0 million minimum for the Global Market. It has until July 2, 2025 to regain compliance, and its 2024 annual report carries a going-concern warning with $5.6 million of cash at June 30, 2024.
IXHLSensei Biotherapeutics told investors on January 7, 2025 that Nasdaq had moved its stock to the Capital Market and given it until July 7, 2025 to lift its share price above $1.00. Its 2023 annual report showed a $34,101 thousand net loss and cash that fell to $13,011 thousand at year end.
FTHThe Nasdaq Hearings Panel kept the stock listed on two conditions: a reverse stock split by January 31, 2025 and a $1.00 close for ten straight trading days by February 14, 2025. The panel confirmed the equity deficiency is cured.
REVBOcugen received a Nasdaq deficiency notice because its stock closed below $1.00 for 30 consecutive business days. It has until June 30, 2025 to regain compliance and may qualify for a second 180-day period.
OCGNThe deal covers 1,000,000 common shares at $2.00 each, plus two series of warrants. H.C. Wainwright & Co. is placement agent.
PBMThe notice lists 482 holders of record of common stock and 480 of Series A preferred stock. It relies on Rule 12h-3(b)(1)(ii).
RGBPThe Nasdaq Hearings Panel denied the company's request to stay listed over the $1.00 minimum bid price rule. Shares are to trade as CYTOF, and the company says it plans no reverse stock split.
CYTOFThe notice, dated December 11, 2024, lists 16 holders of record of its common stock.
NTRRThe notice, dated October 28, 2024, covers the company's redeemable warrants with a $115.00 exercise price, not its common stock.
CLDI
aibio